127 related articles for article (PubMed ID: 37953481)
1. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
2. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
3. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
4. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
6. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
7. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
9. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
11. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.
Samoylova ML; Dodge JL; Yao FY; Roberts JP
Liver Transpl; 2014 Aug; 20(8):937-44. PubMed ID: 24797145
[TBL] [Abstract][Full Text] [Related]
12. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
15. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
Mehta N; Dodge JL; Grab JD; Yao FY
Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
[TBL] [Abstract][Full Text] [Related]
16. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
17. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
